Core Insights - Coeptis Therapeutics is implementing a dual-track model to foster innovation while minimizing reliance on dilutive funding [1][2] - The company is generating revenue alongside its research efforts, demonstrating a sustainable business model in the biotech sector [3][10] Financial Performance - In Q2 2025, Coeptis reported revenue of $200,681 while advancing its GEAR Cell Therapy Platform [3] - The cash position increased from $532,885 at the end of 2024 to $1,996,726 by June 30, 2025, indicating revenue growth rather than dilution [4] - Operating expenses rose to $4.67 million in Q2 2025 from $2.83 million a year earlier, attributed to repositioning costs [9] Market Position - The global cell therapy market is expected to grow from $5.88 billion in 2024 to $44.39 billion by 2034, presenting opportunities for companies with innovative technologies [5] - Coeptis secured exclusive worldwide rights to the GEAR Cell Therapy Platform from Karolinska Institutet, enhancing its NK cell research capabilities [6] Investment Appeal - Hybrid business models are attractive to investors as they reduce dilution risk while maintaining upside potential [7] - Coeptis successfully completed a $10 million Series A preferred stock offering in February 2025, followed by a private placement targeting $2.5–$5 million in July [7] Strategic Operations - The company is managing the complexity of dual-track operations through strategic restructuring, including a pending merger with Z Squared [8] - This merger will allow Coeptis to focus on biotechnology operations while retaining technology assets, enhancing management efficiency [8]